Comparative Pharmacology
Head-to-head clinical analysis: ISMOTIC versus MANNITOL 20.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISMOTIC versus MANNITOL 20.
ISMOTIC vs MANNITOL 20%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isosmotic solution of mannitol; increases plasma osmolality, drawing water from tissues into the vasculature and reducing intracranial/intraocular pressure via osmotic diuresis.
Increases plasma osmolality, drawing water from intracellular and interstitial spaces into the extracellular fluid, thereby reducing intracranial pressure and promoting diuresis.
1-2 g orally every 6-8 hours, maximum 8 g/day; or 1-2 g intravenously over 5-10 minutes every 6-8 hours, maximum 8 g/day.
Adult: 50-100 g intravenously as a 20% solution over 30-60 minutes. For cerebral edema: 0.25-1 g/kg IV over 30-60 minutes. For oliguric acute kidney injury: test dose 0.2 g/kg IV over 3-5 minutes.
None Documented
None Documented
4.5-6.0 hours in adults with normal renal function; prolonged in renal impairment (up to 24-48 hours in anuria)
Terminal elimination half-life 1.1–1.6 hours in normal renal function; prolonged to 18–36 hours in anuria/end-stage renal disease.
Renal: 90-95% unchanged; biliary/fecal: <5%
Renal, >90% unchanged by glomerular filtration; negligible biliary (<2%) or fecal elimination.
Category C
Category A/B
Osmotic Diuretic
Osmotic Diuretic